Cor Triatriatum Sinister Identified after New Onset Atrial Fibrillation in an Elderly Man

por Zepeda, Ignacio A., Morcos, Peter, Castellanos, Luis R.
Publicado 2014

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities

por Morcos, Peter N., Li, Junyi, Hosseini, Iraj, Li, Chi‐Chung
Publicado 2020

Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities

por Fowler, Stephen, Morcos, Peter N., Cleary, Yumi, Martin-Facklam, Meret, Parrott, Neil, Gertz, Michael, Yu, Li
Publicado 2017

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer

por Hsu, Joy C., Jaminion, Felix, Guerini, Elena, Balas, Bogdana, Bordogna, Walter, Morcos, Peter N., Frey, Nicolas
Publicado 2021

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer

por Morcos, Peter N., Nueesch, Eveline, Jaminion, Felix, Guerini, Elena, Hsu, Joy C., Bordogna, Walter, Balas, Bogdana, Mercier, Francois
Publicado 2018

Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Inf...

por Boffito, Marta, Jackson, Akil, Pozniak, Anton, Giraudon, Mylene, Kulkarni, Rohit, Abelardo, Maria Connie, Patel, Indravadan H., Morcos, Peter N.
Publicado 2015

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab

por Morcos, Peter N., Moss, Jonathan, Austin, Rupert, Hiemeyer, Florian, Zinzani, Pier Luigi, Beckert, Vita, Mongay Soler, Lidia, Childs, Barrett H., Garmann, Dirk
Publicado 2023

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

por Morcos, Peter N., Cleary, Yumi, Sturm‐Pellanda, Carolina, Guerini, Elena, Abt, Markus, Donzelli, Massimiliano, Vazvaei, Faye, Balas, Bogdana, Parrott, Neil, Yu, Li
Publicado 2018

Metabolites of alectinib in human: their identification and pharmacological activity

por Sato-Nakai, Mika, Kawashima, Kosuke, Nakagawa, Toshito, Tachibana, Yukako, Yoshida, Miyuki, Takanashi, Kenji, Morcos, Peter N., Binder, Martin, Moore, David J, Yu, Li
Publicado 2017

Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors

por Morcos, Peter N., Schlender, Jan, Burghaus, Rolf, Moss, Jonathan, Lloyd, Adam, Childs, Barrett H., Macy, Margaret E., Reid, Joel M., Chung, John, Garmann, Dirk
Publicado 2023

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

por Jamois, Candice, Gibiansky, Ekaterina, Gibiansky, Leonid, Chavanne, Clarisse, Morcos, Peter N., McIntyre, Christine, Barrett, Martin, Lundberg, Linda, Zharkov, Artem, Boehnke, Axel, Frey, Nicolas
Publicado 2021

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial

por Dziadziuszko, Rafal, Peters, Solange, Mok, Tony, Camidge, D. Ross, Gadgeel, Shirish M., Ou, Sai-Hong Ignatius, Konopa, Krzysztof, Noé, Johannes, Nowicka, Malgorzata, Bordogna, Walter, Morcos, Peter N., Smoljanovic, Vlatka, Shaw, Alice T.
Publicado 2022

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

por Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, Petris, Luigi De, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C., Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Zeaiter, Ali, Shaw, Alice T.
Publicado 2017

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

por Hutchings, Martin, Morschhauser, Franck, Iacoboni, Gloria, Carlo-Stella, Carmelo, Offner, Fritz C., Sureda, Anna, Salles, Gilles, Martínez-Lopez, Joaquín, Crump, Michael, Thomas, Denise N., Morcos, Peter N., Ferlini, Cristiano, Bröske, Ann-Marie E., Belousov, Anton, Bacac, Marina, Dimier, Natalie, Carlile, David J., Lundberg, Linda, Perez-Callejo, David, Umaña, Pablo, Moore, Tom, Weisser, Martin, Dickinson, Michael J.
Publicado 2021